Living AloneNCT03330587
Living Alone in Old Age With Cognitive Impairment
An observational study of Living Alone and Alzheimer Disease, run by University of California, San Francisco at 1 site in United States.
Trial summary
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Living Alone, Alzheimer Disease, Mild Cognitive Impairment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2016to 31 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Persons over 55 years of age living alone and having a medical diagnosis of Alzheimer's disease or mild cognitive impairment
Who may be able to join
- Living alone
- Medical diagnosis of Alzheimer's disease or mild cognitive impairment
Who cannot join
- Living in nursing homes, assistive living facilities.
- Alcohol abuse
Trial locations and contacts
1 site in 1 country.
United States1 site
Institute for Health & Aging
San Francisco, California, 94705
About this study
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment.
We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment.
This study investigates the priorities and concerns of older adults living alone with cognitive impairment. Participants are interviewed 5 times for one hour in their homes within 3 months at a time that works for them.
Read the detailed description
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. This knowledge is important to design programs that are appropriate. Dr. Elena Portacolone, an Assistant Professor from the Institute of Health and Aging is the study researcher.
Study participants are interviewed by Elena at a time and place convenient to them, usually their home. Interviews are audio recorded and last around one hour. Study participants are interviewed five times within 3 months.
After the interview, a transcriptionist will type into a computer the recording and will remove personal names. The sound recording will then be destroyed.
Participants can stop being in the study at any time.
- Conditions
- Living Alone, Alzheimer Disease, Mild Cognitive Impairment
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction
What is being measured
The primary outcome is the main question the study is designed to answer.
Ethnographic interviews
Questions that follow the train of thought of study participants
Measured: One hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2017
- Study start1 Mar 2016
- Primary completion20 Feb 2024 (estimated)
- Study completion31 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Living AloneStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Elena Portacolone, PhD MPH MBA, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03330587
- Sponsor's protocol ID
- R01AG069147
- Status last verified
- Nov 2023
- First submitted
- 24 Aug 2017
- Last updated
- 18 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Living Alone in Old Age With Cognitive Impairment
- ClinicalTrials.gov ID
- NCT03330587
- Acronym / sponsor ID
- R01AG069147
- Conditions
- Living Alone, Alzheimer Disease, Mild Cognitive Impairment
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 1 Mar 2016 (actual)
- Primary completion
- 20 Feb 2024 (estimated)
- Study completion
- 31 May 2025 (estimated)
- First posted
- 6 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment.
We recruit adults 55+ living alone with cognitive impairment such as Alzheimer's disease or mild cognitive impairment.
This study investigates the priorities and concerns of older adults living alone with cognitive impairment. Participants are interviewed 5 times for one hour in their homes within 3 months at a time that works for them.
Detailed description
The purpose of this study is to better understand the experience of living alone in older age with cognitive impairment. This knowledge is important to design programs that are appropriate. Dr. Elena Portacolone, an Assistant Professor from the Institute of Health and Aging is the study researcher.
Study participants are interviewed by Elena at a time and place convenient to them, usually their home. Interviews are audio recorded and last around one hour. Study participants are interviewed five times within 3 months.
After the interview, a transcriptionist will type into a computer the recording and will remove personal names. The sound recording will then be destroyed.
Participants can stop being in the study at any time.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Persons over 55 years of age living alone and having a medical diagnosis of Alzheimer's disease or mild cognitive impairment
Key inclusion criteria (2 listed)
- Living alone
- Medical diagnosis of Alzheimer's disease or mild cognitive impairment
Key exclusion criteria (2 listed)
- Living in nursing homes, assistive living facilities.
- Alcohol abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Ethnographic interviews
Time frame: One hour
Questions that follow the train of thought of study participants
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
- The investigator discusses her studyLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Living Alone
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
RecruitingPhase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Active, not recruitingPhase 3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elena Portacolone, PhD MPH MBA principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Living Alone and Alzheimer Disease, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ethnographic interviews (time frame: One hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.